

CONTENTS

Exhibit 1	FDA March 1, 2004 letter from Gary J. Buehler, Director, Office of Generic Drugs, Center for Drug Evaluation and Research to ANDA Applicants for Metaxalone Tablets
Exhibit 2	Declaration of Dr. Paul Bass, Professor Emeritus of Pharmacology at the University of Wisconsin -- Madison
Exhibit 3	Morey, "Metaxalone, a New Skeletal Muscle Relaxant," J. Am. Osteo. Ass'n, 62:517-21 (1963)
Exhibit 4	Fathie, "Musculoskeletal Disorders and Their Management with a New Relaxant," <i>Clinical Medicine</i> , 72: 679-82 (1965)
Exhibit 5	Carter, "A new muscle relaxant," Diseases of the Nervous System 1962; 23(2): 98-100
Exhibit 6	Albanese, <i>Nurses' Drug Reference</i> at 427 (2d ed. 1982)
Exhibit 7	1990 <i>Physicians' Desk Reference</i> at 831
Exhibit 8	<i>AHFS Drug Information</i> 12:20 at 1325 (2003)
Exhibit 9	Harden, "A review of three commonly prescribed skeletal muscle relaxants," J. of Back and Musculoskeletal Rehab. 15:63-66 (2000)
Exhibit 10	Fathie, "A Second Look at a Skeletal Muscle Relaxant: A Double-Blind Study of Metaxalone," <i>Current Therapeutic Research</i> , Vol. 6., No. 11 :677-83 (1964)
Exhibit 11	Abrams, <i>Clinical Drug Therapy</i> 145-49 (1995)
Exhibit 12	<i>Drug Information for the Health Care Professional</i> , USPDI Vol. I at 2449 (15th ed. 1995)
Exhibit 13	Carroll, "The pharmacology of a new oxazolidinone with anticonvulsant, analgetic and muscle relaxant properties," <i>Arch. Int. Pharmacodyn.</i> , Vol. 80, No. 3-4:280-98 (1961)
Exhibit 14	Hamaguchi, "Effect of a high-fat meal on the bioavailability of phenytoin in a commercial powder with a large particle size," <i>Int'l. J. Clin. Pharmacol., Ther. and Tox.</i> , Vol 31 No. 7:326-330 (1993)
Exhibit 15	Osol, <i>Remington's Pharmaceutical Sciences</i> at 867 (16th ed. 1980)
Exhibit 16	Monograph No. 5838 of the Merck Index (11th ed., 1989)
Exhibit 17	U.S. Patent No. 6,407,128
Exhibit 18	October 2000 FDA Guidance for Industry "Bioavailability and bioequivalence studies for orally administered drug products – General considerations"
Exhibit 19	Draft 1997 Guidance for Industry "Food-effect bioavailability and bioequivalence studies"
Exhibit 20	U.S. Patent No. 6,683,102

Exhibit 21	United States Patent Application No. 10/420,804
Exhibit 22	May 31, 2002 letter from Lee S. Simon, Division Director, Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products, to Linda B. Fischer, Elan Pharmaceuticals, Inc.
Exhibit 23	King Product Information, printed from http://www.kingpharm.com/product_view.asp?KP_Product_ID=101
Exhibit 24	Bass, Capsugel Symposia Series, <i>Current Status on Targeted Drug Delivery to the Gastrointestinal Tract</i> , "Gastric emptying: differences among liquid, fiber, polymer and solid dosage forms of medications," Short Hills, NJ – April 22, 1993.
Exhibit 25	Elan Clinical Study Report ELN151607-105, "A study to evaluate the pharmacokinetics of Skelaxin® (metaxalone) 2x400mg tablet administered to young and elderly volunteers under fed and fasted conditions"